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New Delhi metallo--lactamase 1 (NDM-1) is a key enzyme that the pathogen Klebsiella pneumonia uses to hydrolyze almost all
-lactam antibiotics. It is currently unclear why NDM-1 has a broad spectrum of activity. Docking of the representatives of the
-lactam families into the active site of NDM-1 is reported here. All the -lactams naturally fit the NDM-1 pocket, implying that
NDM-1 can accommodate the substrates without dramatic conformation changes. The docking reveals two major binding
modes of the -lactams, which we tentatively name the S (substrate) and I (inhibitor) conformers. In the S conformers of all the
-lactams, the amide oxygen and the carboxylic group conservatively interact with two zinc ions, while the substitutions on the
fused rings show dramatic differences in their conformations and positions. Since the bridging hydroxide ion/water in the S con-
former is at the position for the nucleophilic attack, the S conformation may simulate the true binding of a substrate to NDM-1.
The I conformer either blocks or displaces the bridging hydroxide ion/water, such as in the case of aztreonam, and is thus inhibi-
tory. The docking also suggests that substitutions on the -lactam ring are required for -lactams to bind in the S conformation,
and therefore, small -lactams such as clavulanic acid would be inhibitors of NDM-1. Finally, our docking shows that moxalac-
tam uses its tyrosyl-carboxylic group to compete with the S conformer and would thus be a poor substrate of NDM-1.
The recent outbreak of colistin- and carbapenem-resistantKlebsiella pneumoniae isolates in Detroit, MI (18, 20) empha-
sizes that multidrug resistance is a major global threat to human
health. Although the mechanisms of multidrug resistance are un-
known, hydrolysis of -lactam antibiotics by -lactamases is the
most common cause of resistance in clinically important Gram-
negative bacteria (3, 4). The number of members of the -lacta-
mases exceeded 890 by late 2009, and -lactamases are categorized
into four classes, A, B, C, and D, on the basis of their sequence
similarity (4). Enzymes in classes A, C, and D are serine -lacta-
mases that contain no divalent metal ions and employ an active-
site serine to hydrolyze their substrates by forming an acyl inter-
mediate (1). Class B consists of metallo--lactamases (MBLs),
most of which typically contain two zinc ions at the active site to
facilitate the -lactam hydrolysis. Class B enzymes can be further
categorized into three subclasses of B1, B2, and B3 (10) and are
regarded as a therapeutic challenge because the vast majority of
the MBL enzymes show a broad spectrum of activity on hydrolysis
of therapeutic -lactams (1).
Recently, a new -lactamase, called New Delhi metallo--
lactamase 1 (NDM-1), has been identified in the pathogenic
bacteria of patients. NDM-1 was originally found in India (8)
and has spread worldwide to countries including Australia
(23), Belgium (2), Canada (16), China (6), Germany (22), Italy
(17), Japan (37), Norway (26), Spain (27), Switzerland (24),
the United Kingdom (15), and the United States (5). NDM-1
has a fold common to the other MBLs and shows the ability to
hydrolyze most -lactams (3).
Hundreds of crystal structures of the -lactamases have been
deposited in the Protein Data Bank (PDB), including the recent
structures of NDM-1 (11, 13, 14, 39). However, no structures of
MBLs in complex with real substrates have been reported. This
situation not only leaves the hydrolysis mechanisms of MBLs elu-
sive but also slows the discovery of effective MBL inhibitors. Al-
though academic and industrial researchers have worked exten-
sively on the discovery of MBL inhibitors for several decades, the
current compounds cannot be used as therapeutics to suppress the
hydrolysis of -lactams by the superbugs (1, 32). Most MBL in-
hibitors, including the compounds that simulate the intermedi-
ates of the reactions, such as mercaptocarboxylate for VIM-2 (35),
show affinity only at the micro- or submicromolar level (32). This
paper explores the bound conformations of the representatives of
the -lactam subfamilies (Fig. 1) by docking simulation. Our
docking reveals a common pattern for binding of the -lactams,
which may simulate the bound conformation of the genuine sub-
strates. The docking also shows that the widely open pocket of
NDM-1, as revealed by the crystal structures (11, 13, 14, 39), can
naturally adopt most -lactams, thus providing valuable hints for
the design of NDM-1 inhibitors.
MATERIALS AND METHODS
The following representatives of the -lactam subtypes were manually
built in a graphic terminal by using the hydrolyzed product of ampicillin
as the starting model (PDB accession number 3Q6X) (39): ampicillin and
sulbactam (penam subfamily), cefotaxime (cephem), moxalactam (ox-
acephem), clavulanic acid (clavam), aztreonam (monobactam), mero-
penem (carbapenem), and faropenem (penem) (Fig. 1). In an assumption
of no changes on the enantiomeric configurations when the -lactam
substrates are converted to their products, the enantiomeric conforma-
tion of the hydrolyzed ampicillin was taken as the template to build the
models of ampicillin and other -lactams since they share two chiral cen-
ters on the -lactam rings (Fig. 1).
The models of the -lactams were docked by the program AutoDock
(version 4.2) (12, 19) into the active site of a monomeric NDM-1 that was
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taken from the dimer in the crystal structure (PDB accession number
3Q6X) (39). The dihedral angles of the -lactam models were optimized
by the program to best fit into the pocket of NDM-1. The docking of
ampicillin was performed against the NDM-1 structures with rigid or
flexible side chains of the active-site residues (Ile35, Leu65, Met67, Val73,
Try93, Asn220), except for the metal binding residues. These two methods
of docking produced overall comparable results. However, the flexible
docking output indicated only 73% poses that bind to the active site of
NDM-1, while 27% poses bind somewhere else. In comparison, the rigid
docking showed 100% poses bound to the active site of NDM-1. There-
fore, the rigid monomeric NDM-1 structure was used for docking of all
other -lactams. A typical box with 60 by 60 by 60 grid points equally
spaced at 0.375 Å per grid was generated using AutoGrid (19). The fol-
lowing parameters and Lamarckian genetic algorithm were used for the
docking: random initial orientation and position, population size of 150,
maximum number of energy evaluations of 25 million, maximum num-
ber of generations of 27,000, mutation rate of 0.02, crossover rate of 0.8,
and 100 docking runs to output 100 docked conformations.
RESULTS
Structure of NDM-1. As shown by the crystal structure (PDB
accession number 3Q6X), NDM-1 shares a common folding ar-
chitecture with other MBLs and contains two zinc ions as its cat-
alytic metals that chelate with His120/His122/His189 and Asp124/
Cys208/His250, respectively (11, 13, 14, 39). The monomer of
NDM-1 contains five major helices and 12  strands that are
marked H1 to H5 and S1 to S12 in Fig. 2, following the class B
-lactamase (BBL) numbering scheme (9). However, NDM-1
contains a short helix before H2 and a short strand after H3 and
also has a helix in the place of S8 of other MBLs (9). The active-site
pocket of NDM-1 in the crystal structures (11, 13, 14, 39) is widely
open, with two zinc ions sitting in the bottom of the cavity.
Docked conformations of the -lactams. The program Auto-
Dock (version 4.2) (12) automatically groups the 100 output
poses into clusters when their overall root mean square deviations
(RMSDs) are less than 2 Å. However, this classification does not
well present the key feature of the -lactam binding. We alterna-
tively reclustered the outputs on the basis of the interactions of the
carboxylic and carbonyl groups of -lactams, which are two key
functional groups for the catalysis and are shared by all -lactams,
with the zinc ions of NDM-1 (Fig. 1). Thus, all the docked poses of
the -lactams can be categorized into two binding modes. In the
FIG 1 Chemical structures of -lactams.
FIG 2 Structure of NDM-1 (drawn from PDB accession number 3Q6X). (A) Ribbon diagram of NDM-1. The  helices and  stands are marked H1 to H5 and
S1 to S12, respectively, following the BBL numbering scheme (9). However, NDM-1 has a helix to correspond to S8 of the BBL scheme and contains a short helix
before H2 and a short  strand after H3. (B) Surface presentation of NDM-1. Red, oxygen; blue, nitrogen; white, carbon.
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first mode, the carbonyl oxygen of the amide of -lactams coor-
dinates with zinc ion 1 (Zn1) (Fig. 3A), while the carboxylic oxy-
gen of the fused rings chelates with zinc ion 2 (Zn2). Since the
binding geometry in this mode is ready for the nucleophilic attack
by the bridging hydroxide ion/water, which is a widely accepted
mechanism for -lactam hydrolysis found by people in the field of
MBLs (7, 13, 28, 33, 39), we tentatively name this binding mode
the S (substrate) conformer. In the second mode, the carboxylic
group of -lactams either displaces the bridging hydroxide ion/
water (Fig. 3B) or simultaneously coordinates with both zinc ions
to switch the amide group away from the metal ions (Fig. 3C). As
the result, the hydrolysis of -lactams is abolished in the second
binding mode, and thus, we tentatively name it the I (inhibitor)
conformer.
In the S conformers, the distance between negatively charged
carboxylic oxygen of -lactams and positively charged Zn2 of
NDM-1 is 1.6 to 1.7 Å, while the distance between the carbonyl of
-lactam amide and Zn1 varies over a range of from 1.7 to 2.8 Å
for the docked poses with the lowest energy (Table 1). The car-
bonyl and carboxylic oxygens of the -lactams form distorted
tetrahedrons, respectively, with Zn1 and Zn2 in all the S conform-
ers, in spite of a slight variation in the positions of the fused -lac-
tam rings in each docked conformation. This binding geometry
implies that zinc ions play an essential role in the substrate binding
and the catalysis and is consistent with the early proposal (25). The
interactions of the S or I conformers with the zinc ions are con-
served in all the docked -lactams and are thus understood in the
following description of the binding of individual -lactams.
Ampicillin. The 100 docked conformations of ampicillin were
categorized into five clusters by AutoDock (version 4.2) and re-
grouped into the S and I conformers, which count for populations
of 89% and 11%, respectively (Table 2). The lowest binding ener-
gies of the S and I conformers were 12.07 and 11.74 kcal/mol,
respectively, corresponding to the estimated Ki values of 1.4 and
2.5 nM, respectively. A plot of all the 89 S conformers together
shows that the positions of the -lactam ring and the interactions
of the carboxylic and carbonyl groups with the zinc ions are con-
served, with a root mean standard deviation of 1 Å (Fig. 4A).
However, the conformation and position of the phenyl group of
ampicillin vary dramatically, forming a pattern like the open tail
of a peacock (Fig. 4A). It is unknown which phenyl conformation
of ampicillin would simulate the substrate binding, although the S
conformer with the lowest binding energy is well superimposed
over the hydrolyzed ampicillin in the crystal structure of NDM-1
(Fig. 4B). The S conformer with the lowest binding energy inter-
acts with NDM-1 in a pattern similar to that for the reaction prod-
uct in the crystal structure of NDM-1 (PDB accession number
3Q6X) (39), except for the hydrogen bond between Asn220 and
the hydrolyzed ampicillin (Fig. 4B). The S conformer with the
lowest binding energy forms three hydrogen bonds with Nz of
Lys211, OE1 of Gln123, and the backbone nitrogen of Asp124, in
addition to the van der Waals interactions with Ile35 Leu65,
Met67, Val73, Trp93, and Asn220 (Fig. 4B). The I conformer with
the lowest energy forms no hydrogen bonds but has van der Waals
contacts with Ile35, Leu65, Met67, Val73, Trp93, and Asn220
(Fig. 4C).
Cefotaxime. The five clusters of cefotaxime output from the
program AutoDock (version 4.2) were reclassified into the S and I
conformers, which have populations of 71% and 29%, respec-
tively, and estimated Ki values of 1.5 and 0.04 nM, respectively
(Table 2). The superposition of all the S conformers shows that the
positions of the -lactam ring and the interactions of the carbox-
ylic and carbonyl groups with the zinc ions are well comparable
(Fig. 4D). However, two substitutions on the -lactam ring dra-
matically change their position and conformation (Fig. 4D). The S
conformer with the lowest binding energy forms four hydrogen
bonds with Gln123, Glu152, Lys211, and Asp223 (Fig. 4E), while
the I conformer forms nine hydrogen bonds with Gln123, Asp124,
Glu152, Lys211 Asn220, and Asp223 (Fig. 4F). Both S and I con-
formers show van der Waals interactions with Ile35, Val73, Trp93,
and Gln123.
Faropenem. AutoDock (version 4.2) outputs only three clus-
ters for faropenem, which correspond to 14% S conformers (the
best Ki, 1.3 nM) and two I conformers, I1 and I2 (74% population
and Ki of 0.4 nM for I1 and 12% population and Ki of 1.7 nM for
I2; Table 2). The I1 and I2 conformers have the opposite orienta-
tions of the -lactam ring. The S conformer with the lowest energy
forms five hydrogen bonds with Gln123, Asp124, Lys211, and
Asn220, in addition to the van der Waals interactions with Ile35,
Val73, and Trp93. The I conformer with the lowest energy forms
two hydrogen bonds with Asn220 and His250, in addition to the
van der Waal contacts with Ile35, Val73, Trp93, Gln123, Glu152,
and Asp223.
Imipenem. Imipenem had a wide distribution of the docked
conformations, as shown by the output of nine clusters from Au-
toDock (version 4.2). The S conformers count for 69% of the




















FIG 3 Potential interactions of -lactams with the zinc ions of NDM-1. (A)
Proposed active form of the -lactam interaction with the zinc ions. The bridg-
ing OH would perform the nucleophilic attack. R1 and R2, substitutions of
-lactams. (B and C) Two types of inhibitory interactions of -lactams with
the zinc ions.
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population and can be further grouped into two conformations
(62% and 7%; Table 2) in which the -lactam ring has the oppo-
site orientations and thus switched interactions of the carbonyl
and carboxylic groups with Zn1 and Zn2. The I conformers of
imipenem can also be divided into two groups, I1 and I2, in which
I1 (17%) and I2 (14%) have the opposite orientations of their
-lactam rings. The S conformer with the lowest energy forms two
hydrogen bonds with the side chain nitrogen of Lys211 and back-
bone carbonyl of Leu218, in addition to van der Waal contacts
with Ile35, Val73, Trp93, and Asn220. The I conformer with the
lowest energy forms two hydrogen bonds with Glu152 and
Asp223, in addition to van der Waals interactions with Leu65,
Met67, Val73, Trp93, and Asn220.
Aztreonam. Aztreonam is the only -lactam that contains no
fused ring (Fig. 1). The 100 poses have a wide distribution of
conformations and were grouped into 14 clusters. However, all
the conformers have the sulfate group of aztreonam either block-
ing (93%) or displacing (7%) the bridging hydroxide/water and
are thus inhibitory (Table 2). The I conformer with the lowest
binding energy has a sulfate group coordinating with both zinc
ions and forms two hydrogen bonds with Gln123 (Fig. 4G), in
addition to van der Waals interactions with Leu65, Met67, and
Trp93.
Clavulanic acid. The 100 poses of clavulanic acid unanimously
have the I conformation (Table 2). The I conformer with the low-
est binding energy forms two hydrogen bonds with the backbone
nitrogen atoms of Gln123 and Asp124, in addition to the van der
Waals interactions with Val73, Trp93, Gln123, and Asn220
(Fig. 4H).
DISCUSSION
Evaluation of docking results. Since the docked pose with the
lowest binding energy does not always represent the true binding
of a ligand in a biological system (34), an auxiliary standard would
be required to identify the true conformation of ligand binding.
We feel that the population of clusters from the docking might be
a helpful hint for judgment of the correct conformation simulat-
ing ligand binding in a biological system. The -lactams with a
large population of the S conformer, such as ampicillin, would be
expected to be substrates of NDM-1, while the large population of
the I conformer would indicate a poor substrate. This prediction
for NDM-1 is in general consistent with the experimental results
(Table 2). However, the population of clusters would not have a
quantitative meaning for analysis of docking results, and the pop-
ulation percentile that defines whether a -lactam behaves as a
substrate or an inhibitor would vary in individual cases. Besides,
TABLE 2 Summary of -lactam docking to NDM-1a
-Lactam














Ampicillin 22 2.2 12.07 1.4 89 11.74 2.5 11
Penicillin G 16 3.0 12.35 0.9 79 12.53 0.7 21
Piperacillin 12 12.70 0.5 97 11.56 3.4 3
Cefepime 77 11.29 5.3 83 12.18 1.2 17
Cefotaxime 10 12.04 1.5 71 14.23 0.04 29
Cefoxitin 49 10.61 16.7 51 12.32 0.9 26
12.58c 0.6c 4c 11.10d 7.3d 11d
13.46e 0.1e 8e
Ceftazidime 181 11.02 8.4 8 12.7 0.5 86
11.25d 5.7d 6d
Cefuroxime 8 12.06 1.4 45 12.57 0.6 55
Cephalothin 10 11.90 1.9 35 14.30 0.03 62
12.02d 1.5d 3d
Faropenem 12.11 1.3 14 12.76 0.4 74
11.96d 1.7d 12d
Imipenem 94 4.3 10.39 24.2 62 11.31 5.2 17
10.18c 34.4c 7c 10.79d 12.2d 14d
Meropenem 49 2.6 10.64 15.8 84 11.65 2.9 5
11.59c 3.2c 11c
Clavulanic acid Not detected 11.44 4.1 100
Aztreonam Not detected 12.84 0.4 93
12.38e 0.8e 7e
Sulbactam 10.79 4.7 17 11.61 3.1 57
11.55d 3.4d 26d
Moxalactam 10.97 9.1 1
15.12f 0.008f 99f
a In the S conformer, the amide oxygen of the -lactams interacts with Zn1, while the carboxylic group coordinates with Zn2. The I conformer has the carboxylic or sulfate oxygens
interacting with Zn1 and Zn2.
b The Km and kcat/Km values are taken from the papers by Yong et al. (38) and by Thomas et al. (28), respectively.
c The S2 conformer has switched interactions with the zinc ions from the S conformer.
d The I2 conformer has the orientation of the carboxylic group opposite that of I1.
e In the I3 conformer, the bridging hydroxide/water is displaced by the carboxylic or sulfate oxygen.
f In the I4 conformer, the tyrosyl-carboxylic group chelates with the zinc ions.
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FIG 4 Docking of -lactams into the NDM-1 binding pocket. (A) A plot of all S conformers of docked ampicillin (total, 89 sticks) into the NDM-1 active site
(surface presentation). Positional variation of the phenyl groups forms a pattern like the open tail of a peacock. (B) Interactions between NDM-1 and the S
conformer (green sticks) of ampicillin with the lowest binding energy. The dotted lines represent hydrogen bonds or coordination with the metals. The
hydrolyzed ampicillin from the crystal structure of the NDM-1-product complex (PDB accession number 3Q6X) is plotted with yellow sticks. (C) Interactions
of the I conformer of ampicillin with NDM-1. (D) Binding of all the S conformers (71 total) of cefotaxime to the NDM-1 pocket. (E) Interactions of the S
conformer of cefotaxime with NDM-1. (F) Interactions of the I conformer of cefotaxime with NDM-1. (G) An inhibitory conformation of aztreonam. (H) A
representative binding of clavulanic acid. (I) An inhibitory binding of moxalactam (latamoxef) to NDM-1 in which the tyrosyl-carboxylic group of moxalactam
interacts with both zinc ions.
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the estimated Ki values of the -lactams from AutoDock (version
4.2) are about 3 to 4 orders of magnitude better than the experi-
mental data (Table 2) and possibly result from the parameter set-
tings of the program. Therefore, the docking may qualitatively
identify a substrate or an inhibitor and would be a relative means
for comparison of -lactams.
Potential bound conformations of -lactam substrates.
Since no crystal structures of any MBLs in complex with a sub-
strate have been reported, the bound conformations of the -lac-
tam substrates remain veiled. Our docking experiments reveal
that the -lactams bound to the active site of NDM-1 in either the
S or I conformation (Table 2; Fig. 4). In the S conformation, the
interactions between the zinc ions of NDM-1 and the amide and
carboxylic oxygens of the -lactams are comparable for all the
-lactam substrates that have been docked, while the substitutions
on the -lactam rings dramatically change their conformations
and positions (Fig. 4). Therefore, we hypothesize that the confor-
mations and interactions of the -lactam rings in the S conform-
ers must simulate the true binding of the -lactam substrates to
NDM-1. This hypothesis is supported by several lines of evidence.
First, the interactions of the docked S conformation of ampicillin
with the lowest binding energy are similar to those of the hydro-
lyzed product, as shown by the structure superposition in Fig. 4B,
except for the hydrolyzed ring of ampicillin. Second, in the S con-
formers, the bridging hydroxide/water is located at a position
about 4 Å away from the amide carbon of the -lactams and may
thus be ready for nucleophilic attack. This pathway is consistent
with the hydrolysis mechanism that has been unanimously pro-
posed by several research groups (7, 21, 28–30, 33, 39). Third, the
chelation of the amide oxygen of the -lactams with Zn1, which
was proposed to be an essential configuration of the catalysis on
the basis of the crystal structures of IND-7 (36) and NDM-1 (39),
is similar to that in the S conformers. Last and most importantly,
our docking results are, in general, consistent with the enzymatic
property of the -lactam substrates. All -lactam substrates that
can be hydrolyzed by NDM-1 (28, 38) can be docked with a sig-
nificant percentage of the S conformers, while the -lactams that
are resistant to NDM-1 hydrolysis, such as aztreonam and clavu-
lanic acid, were docked in only I conformers (Table 2).
Insight into the broad spectrum of activity of NDM-1. It has
been puzzling how NDM-1 is capable of hydrolyzing almost all
antibiotics containing the -lactam scaffold (31). The docking of
the various -lactams described in this paper provides a hint to
this puzzle. Since the docking experiments were to fit variable
conformations of the -lactams into the rigid NDM-1 pocket, the
good accommodation of all the -lactams to the active site of
NDM-1 must imply no global or allosteric conformation changes
upon the binding of -lactams. Instead, the widely open binding
pocket of NDM-1 in the crystal structure (Fig. 2B) may adopt
-lactams with a variety of substitutions, although minor changes
of local conformation around the binding pocket of NDM-1
might be possible, too. If so, the minor conformational changes
would likely be associated with the N-terminal fragment around
S3 (Fig. 2A) that has significant variation in sequence and three-
dimensional conformation across MBL families, but this is yet to
be confirmed by the crystal structure of NDM-1 in complex with
substrates.
Hints on design of NDM-1 inhibitors. Discovery of clinically
usable inhibitors of any MBLs has not been successful (1, 32).
Our docking provides some hints on the design of NDM-1
inhibitors. The docking suggests that the high electrophilicity
of the NDM-1 binding pocket with two zinc ions on its bottom
may be the major binding force and thus prefers to bind nega-
tively charged inhibitors. This hypothesis is consistent with the
early argument that zinc ion plays critical roles both in the
binding of substrates and in the hydrolysis of -lactams (25).
The neighboring of the amide oxygen and carboxylic group of
the fused rings in most -lactams matches well with the geom-
etry of the zinc pocket (Fig. 3 and 4) and may thus explain why
most MBL enzymes have a wide spectrum of activity. On the
basis of this observation, we expected that a -lactam contain-
ing an additional negatively charged group would compete
with binding of the S conformer of a substrate and thus inhibit
the enzyme activity. For example, 99 out of 100 docked confor-
mations of moxalactam have its tyrosyl-carboxylic group in-
stead of the carboxylic group on the fused ring of -lactams
interacting with the zinc ions (Fig. 1 and 4I). Thus, moxalactam
would be expected to be a pool substrate or even an inhibitor of
NDM-1, although this possibility needs to be confirmed by
enzymatic assay. Another example is aztreonam. The nega-
tively charged sulfate group of aztreonam either blocks or re-
places the bridging hydroxide/water in all docked conforma-
tions (Fig. 4G), suggesting that aztreonam would behave as an
inhibitor. This prediction is consistent with the enzymatic as-
say, in that no hydrolysis activity of NDM-1 was detected (38).
In addition to the electrophilic interactions with the zinc ions,
the interactions of the remaining pockets of NDM-1 would also be
important to determine whether a -lactam works as a substrate
or an inhibitor. Since the negatively charged carboxylic group has
a stronger tendency to chelate with two positively charged zinc
ions and thus to inhibit the NDM-1 activity, a helper is necessary
to orient the -lactam ring in a correct position to chelate with the
zinc ions in the S conformation. This may be achieved by a rela-
tively large substitution that links to either side of the lactam ring.
Thus, the -lactams without large substitutions would behave as
an inhibitor, as observed in the case of clavulanic acid, in which
the 100% poses in the I conformation from our docking (Fig. 1
and 4H) agreed well with no detection of hydrolysis by NDM-1
(38). In addition, the majority of a small -lactam, sulbactam (Fig.
1), was docked in the I conformation (83%; Table 2), and sulbac-
tam would thus be expected to be a poor substrate.
Conclusions. (i) The docked S conformation, in which the
amide oxygen and carboxylic acid of -lactams interact, respec-
tively, with Zn1 and Zn2, may simulate the binding of a true sub-
strate to NDM-1. (ii) The natural fit of various -lactams into the
rigid pocket of NDM-1, as revealed by the docking, suggests that
no dramatic conformation changes are required for NDM-1 to
recognize -lactam substrates. (iii) Substitutions on the fused
-lactam ring are essential for -lactams to bind in the S confor-
mation, and thus, small -lactams such as clavulanic acid may
behave as inhibitors. (iv) -Lactams with an additional negatively
charged group, such as moxalactam, may disturb the substrate
binding in the S conformation and may thus be a poor substrate or
even an inhibitor.
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